Oncozenge (Sweden) Today
| ONCOZ Stock | SEK 3.78 0.12 3.08% |
Performance0 of 100
| Odds Of DistressOver 64
|
Oncozenge is selling for under 3.78 as of the 16th of December 2024; that is 3.08 percent decrease since the beginning of the trading day. The stock's lowest day price was 3.64. Oncozenge has more than 64 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 27th of December 2022 and ending today, the 16th of December 2024. Click here to learn more.
OncoZenge AB , a pharmaceutical company, develops healthcare products for cancer supportive care. OncoZenge AB is a subsidiary of Moberg Pharma AB . OncoZenge is traded on Stockholm Stock Exchange in Sweden. The company has 11.71 M outstanding shares. More on Oncozenge AB
Moving against Oncozenge Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Oncozenge Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Oncozenge's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Oncozenge or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Oncozenge AB (ONCOZ) is traded on Stockholm Exchange in Sweden and employs 2 people. The company currently falls under 'Micro-Cap' category with a current market capitalization of 69.46 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Oncozenge's market, we take the total number of its shares issued and multiply it by Oncozenge's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Oncozenge AB operates under Healthcare sector and is part of Biotechnology industry. The entity has 11.71 M outstanding shares.
Oncozenge AB has accumulated about 56.96 M in cash with (4.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.86, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Oncozenge Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Oncozenge AB is kr69.46 Million. Oncozenge has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Oncozenge Ownership Details
Oncozenge AB Risk Profiles
Although Oncozenge's alpha and beta are two of the key measurements used to evaluate Oncozenge's performance over the market, the standard measures of volatility play an important role as well.
Oncozenge Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Oncozenge without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Analyzer Now
Portfolio AnalyzerPortfolio analysis module that provides access to portfolio diagnostics and optimization engine |
| All Next | Launch Module |
Oncozenge Corporate Management
Elected by the shareholders, the Oncozenge's board of directors comprises two types of representatives: Oncozenge inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oncozenge. The board's role is to monitor Oncozenge's management team and ensure that shareholders' interests are well served. Oncozenge's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oncozenge's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Beveridge | Chief Officer | Profile | |
| Markus MD | Chief Officer | Profile | |
| Paul MSc | Chief Officer | Profile | |
| Pirkko Tamsen | Chief Officer | Profile |
Additional Tools for Oncozenge Stock Analysis
When running Oncozenge's price analysis, check to measure Oncozenge's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncozenge is operating at the current time. Most of Oncozenge's value examination focuses on studying past and present price action to predict the probability of Oncozenge's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncozenge's price. Additionally, you may evaluate how the addition of Oncozenge to your portfolios can decrease your overall portfolio volatility.